Satralizumab Slashes Relapse Rate in Neuromyelitis Optica Satralizumab Slashes Relapse Rate in Neuromyelitis Optica

First results from a phase 3 study suggest the biologic agent in development could improve outcomes among people with neuromyelitis optica spectrum disorder.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news